Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Misses Expectations By $0.01 EPS

Heron Therapeutics (NASDAQ:HRTX) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01), FiscalAI reports. The firm had revenue of $34.71 million during the quarter, compared to analysts’ expectations of $36.72 million.

Here are the key takeaways from Heron Therapeutics’ conference call:

• Net product sales were $34.7 million in Q1, modestly below plan after seasonal co-pay resets and two weeks of severe weather that sharply reduced elective surgeries; management notes March recovered to >$15M and expects rescheduled procedures to provide a tailwind through 2026.
• Acute care momentum — acute revenue grew 32% YoY with ZYNRELEF up 27% and APONVIE >50%; ZYNRELEF demand units rose 22% YoY and Ignite 2.0 expanded targeted accounts by 38%, supporting a planned Q3 salesforce expansion.
• APONVIE commercial and clinical catalysts — demand units grew 68% YoY, ordering accounts hit an all‑time high, a permanent J‑Code became active April 1, and APONVIE received an A1 evidence rating and prominent inclusion in the 5th consensus PONV guidelines.
• CINVANTI stability — maintained a ~25% NK1 market share and consistent ordering patterns despite competition, with the REIGNITE program and aprepitant salesforce expansion expected to add roughly $10M of annualized revenue from new accounts.
• Margin and temporary supply cost pressure — growth margin dipped to 69% and adjusted EBITDA was negative $0.7M due in part to higher-cost batches from a secondary CINVANTI supplier; the company expects this to work through over the next two quarters and has reaffirmed full‑year guidance of $173–183M sales and $10–20M adjusted EBITDA.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $0.96 on Tuesday. Heron Therapeutics has a one year low of $0.74 and a one year high of $2.30. The company has a market cap of $180.21 million, a price-to-earnings ratio of -7.35 and a beta of 1.70. The company has a debt-to-equity ratio of 10.59, a quick ratio of 1.51 and a current ratio of 2.48. The business’s 50 day moving average price is $0.97 and its 200 day moving average price is $1.15.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Finally, Zacks Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.50.

Hedge Funds Weigh In On Heron Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC lifted its position in Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after buying an additional 18,114 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Heron Therapeutics during the second quarter worth approximately $26,000. Voleon Capital Management LP purchased a new stake in Heron Therapeutics in the third quarter valued at $34,000. Mercer Global Advisors Inc. ADV purchased a new stake in Heron Therapeutics in the third quarter valued at $34,000. Finally, Russell Investments Group Ltd. purchased a new stake in Heron Therapeutics in the second quarter valued at $43,000. Hedge funds and other institutional investors own 80.01% of the company’s stock.

Trending Headlines about Heron Therapeutics

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Heron said it is being helped by acute care revenue growth and reaffirmed its 2026 guidance, suggesting management still sees the full-year plan as achievable. Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline
• Neutral Sentiment: The company’s Q1 2026 earnings call transcript and press release were released, giving investors more detail on the quarter and management’s outlook, but no major new catalyst beyond the reported results. Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Short-interest data showed 0 shares reported, which does not point to a meaningful change in bearish positioning.
• Negative Sentiment: The quarter’s EPS and revenue both missed estimates, reinforcing concerns that demand or execution remains uneven despite the reaffirmed outlook. Heron Therapeutics earnings report and conference call

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.